Tonix shares traded higher in early May after the company reported first-quarter earnings. The stock is up approximately 99% over the past month and has climbed more than 325% over a three-month ...

Tonix Pharmaceuticals Holding Corp. CHATHAM, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology ...

CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development ...

(MENAFN- GlobeNewsWire - Nasdaq) CHATHAM, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully ...

Tonix Pharmaceuticals Holding Corp. announced the participation of its CEO, Seth Lederman, M.D., in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase, with a webcast available on ...

(MENAFN- Investor Brand Network) Tonix Pharmaceuticals (NASDAQ: TNXP) a fully integrated biotechnology company with commercial and clinical-stage assets, will deliver a poster presentation at the ...

CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development ...

Tonix is a fully-integrated biotech company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix's development portfolio is focused on central nervous ...

Tonix is a fully-integrated biotech company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1-3 Tonix created TNX-1500, a next generation anti-CD40L mAb, by reengineering the Fc region of ruplizumab, to preserve activity with improved safety. The results of the Phase 1 study indicate ...